ROBERT L. SHIELDS, M.D. GLAUCOMA SURGERY AND TREATMENT

Transcription

1 1 CURRICULUM VITAE ROBERT L. SHIELDS, M.D. GLAUCOMA SURGERY AND TREATMENT University of Colorado Health Eye Center Cherry Creek 2000 South Colorado Boulevard Annex Building, Suite 100 Denver, Colorado Appointments: GLAUCOMA PRIVATE PRACTICE: 1) Glaucoma Fellow, University of Wisconsin Medical School, Madison, Wisconsin Paul Kaufman, M.D., Program Director 2) Solo Practice, ) Limited to Glaucoma Consultation and Management, 1985 to ) University of Colorado Hospital(UCH),associate professor, 2012 to present CERTIFICATION: 1) 1981 Board Certified, American Board of Ophthalmology 2) Basic Life Support Certification, 1995 Porter Memorial Hospital 3) Basic Life Support Re-Certification, 2013 American Heart Association 4) Colorado License - # ) DEA - #AS ) UPIN - #D ) Medicare Provider - #81481

2 2 8) Colorado Medicaid - # ) NPI - # CURRENT APPOINTMENTS AND SOCIETIES: 1) Glaucoma Clinic, Associate Clinical Professor, University of Colorado Health Sciences Center 1996 to Present 2) Colorado Ophthalmologic Society: Member 1982 to Present 3) American Glaucoma Society: Member 1988 to Present 4) Rocky Mountain Ophthalmic Consultants: Member 1994 to Present 5) Mountain Medical Affiliates: Member 1999 to 2005, Credentials Committee PAST EDUCATION, SOCIETIES, APPOINTMENTS: A. SOCIETIES AND APPOINTMENTS: HMS Colorado, Credentialing Committee Rotary Club of Denver: Member Glaucoma Clinic, Assistant Professor of Ophthalmology, University of Colorado Health Sciences Center Arapahoe Medical Society: Member Colorado Medical Society: Member Porter Memorial Hospital Foundation: Board Member International Perimetric Society: Member Board of Directors, Rocky Mountain Ophthalmic Personnel

3 Chairman, Department of Ophthalmology, Porter Memorial Hospital Secretary, Octopus Users' Society Assistant Chairman, Department of Ophthalmology, Porter Memorial Hospital Octopus Users' Society: Member B. EDUCATION: Glaucoma Fellow, University of Wisconsin Medical School; Madison, Wisconsin Ophthalmology Residency, University of Colorado Medical Center; Denver, Colorado Rotating Internship, Presbyterian Medical Center; Denver, Colorado Medical School, University of Colorado Medical Center; Denver, Colorado 1975 Fall Bella Bella, British Columbia, Family Practice Rotation, University of Washington; Seattle, Washington, General Surgery Rotation 1971 Summer Denver University; Denver, Colorado Cornell University, Engineering Physics; Ithaca, New York 1965 Summer American University; Saltillo, Mexico George Washington High School; Denver, Colorado RESEARCH - PRINCIPLE INVESTIGATOR 09/96-03/99 Alcon A two-year multi-center, triple-masked, parallel group comparison of the effect of Betaxolol 0.25% and Timolol Maleate 0.5% on the progression of visual field loss and optic nerve head morphology in patients with primary open-angle glaucoma. 09/96-03/99 Allergan The long-term safety and ocular hypotensive efficacy of Brimonidine Tartrate 0.2% in subjects with open-angle glaucoma or ocular hypertension. 08/97-04/99 Pharmacia A six-month, randomized, double-masked comparison of fixed combination of Latanoprost and Timolol with individual components, continuing into a six-month open label safety study of fixed combination in subjects with

4 4 glaucoma or ocular hypertension. 02/98-09/99 Alcon A six-month multi-center, triple masked, parallel group, to establish the safety and the intraocular pressure lowering efficacy of two concentrations of AL % and 0.004% compared with Timolol 0.5% in patients with openangle glaucoma or ocular hypertension. 03/99-07/04 Pharmacia A randomized, five-year, post marketing safety study of Xalatan compared to "usual care" in patients with open-angle glaucoma or ocular hypertension. 05/99-07/00 Allergan A randomized, one-year study, phase III trial, to evaluate the safety and efficacy of an ocular hypotensive lipid compound compared with Timolol on patients with glaucoma or ocular hypertension. 12/99-12/00 Allergan (Cosopt) A randomized, parallel study of the safety and efficacy of AGN % ophthalmic solution q.d. compared to Cosopt ophthalmic solution b.i.d. in subjects with glaucoma or ocular hypertension who are uncontrolled on beta-blocker therapy alone. 01/00-12/01 Allergan (Alphagan) A multi-center, double-masked, randomized, parallel study of the safety of 0.2% Brimonidine Tartrate/0.5% Timolol combination compared to Timolol or Alphagan alone in patients with glaucoma or ocular hypertension. 01/01-01/02 Allergan A multi-center, investigator masked, randomized, parallel study of the efficacy and safety of Lumigan q.d. administered adjunctively with Brimonidine 0.2%, b.i.d. compared with Latanoprost 0.005% q.d. administered adjunctively with Timolol 0.5% b.i.d. in patients with glaucoma or ocular hypertension. 05/01-12/01 Merck A parallel randomized, observer-masked, multi-center study comparing ocular hypotensive effect of Cosopt to concomitant administration of 0.2% Brimonidine Tartrate and 0.5% Timolol Maleate in patients with elevated intraocular pressure. 08/01-09/03 Allergan A multi-center, double masked, randomized, 3-arm parallel study for three months with a nine-month, masked extension) of the safety and efficacy of Bimatoprost 0.03%/Timolol 0.5% combination once daily compared with Timolol 0.5% monotherapy twice daily and Bimatoprost 0.03% monotherapy once daily in patients with glaucoma or ocular hypertension. 10/02-12/03 Alcon (Travatan) A multi-center, double-masked, randomized, parallel study of the safety and efficacy of Travoprost 0.004% / Timolol 0.5%, to the concomitant administration of Travatan and Timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. 01/06-10/07 Allergan (Lumigan) A multi-center double-masked, randomized parallel,

5 5 active controlled, three-month study (plus nine-month masked extension) of the safety and efficacy of Bimatoprost ophthalmic solution 0.01% and Bimatoprost ophthalmic solution % once-daily compared with Lumigan (Bimatoprost ophthalmic solution) 0.03% once-daily in patients with glaucoma or ocular hypertension. 02/06-05/06 Alcon A double-masked, randomized, parallel group, multicenter, non-inferiority design three-month study to determine the safety and efficacy of a new formulation of Travoprost 0.004% without benzalkonium chloride compared to that of the marketed formulation of Travoprost 0.004% (Travatan) in patients with open-angle glaucoma or ocular hypertension. 03/03 05/04 Allergan A multi-center, double-masked, randomized, parallel three-month study (plus a nine-month, masked extension) of the safety and efficacy of 0.1% Brimonidine purite ophthalmic solution dosed three times daily compared with 0.15% Brimonidine purite ophthalmic solution dosed three times daily in patients with glaucoma or ocular hypertension. 03/04 03/006 Allergan A masked histological evaluation of trabecular meshwork specimens collected from trabeculectomy patients with primary open-angle glaucoma treated with Bimatoprost 0.03% ophthalmic solution one daily for at least two-years compared with primary open-angle glaucoma patients treated with other topical ophthalmic intraocular pressure lowering drugs. 06/08 10/09 Alcon A one-year study on the safety and IOP lowering efficacy of anecortove acetate in patients with open-angle glaucoma or ocular hypertension. 07/08 10/09 Alcon A double-masked, multi-center, randomized study of the safety and intraocular pressure lowering efficacy of anecortove acetate in patients with openangle glaucoma or ocular hypertension. RESEARCH: SUB-INVESTIGATOR 06/96-10/96 Alcon A three-month adjunctive therapy study of topical CAI dosed TID. Merck - Timolol/Dorzolamide Component Comparison Study - Oral CAI/Topical CAI switch - Timolol vs Timolol XE 04/96-12/96 Allergan - Brimonidine vs. Dorzolamide, three-month safety, efficacy, and patient acceptability. Long-term safety and efficacy of Brimonidine. 07/96-04/97 Merck A multiple dose, double-masked active treatment controlled, two-period crossover study of 2% preservative-free Dorzolamide and 2.0% Dorzolamide with

6 6 preservative in patients with elevated intraocular pressure. 12/96-09/98 Allergan A six-month clinical study comparing the efficacy and tolerability of Alphagan and Trusopt in subjects with chronic open-angle glaucoma or chronic ocular hypertension presently on topical beta blockers. 12/96-09/98 Allergan A six-month clinical study comparing the efficacy and tolerability of Alphagan and Xalatan in subjects with chronic open-angle glaucoma or chronic ocular hypertension presently on a topical beta-blocker and either Pilocarpine or Trusopt. PAPERS/LECTURES: 1) PREDICTIVE VALUE FOR GLAUCOMA, 1980 COLORADO OPHTHALMOLOGICAL SOCIETY 2) STATIC PERIMETRY FLUCTUATIONS, 1983, 2nd OCTOPUS USERS' SOCIETY 3) EARLY OCTOPUS FIELD DEFECTS, 1984, 3rd OCTOPUS USERS' SOCIETY 4) STATUS REPORT - IBM PC/XT SOFTWARE, 1985, 4th OCTOPUS USERS' SOCIETY 5) SCOTOMA MOVEMENT, th OCTOPUS USERS' SOCIETY 6) SERIAL POINT-BY-POINT TREND ANALYSIS, 1987, 6th OCTOPUS USERS' SOCIETY 7) STAGING OF VISUAL FIELDS, th OCTOPUS USERS' SOCIETY 8) DATA VISUALIZATION -PERIMETRIC IMAGING, 1988, PACIFIC COAST OTO-OPHTHALMOLOGICAL SOCIETY 9) SECONDARY GLAUCOMA ASSOCIATED WITH STURGE WEBER SYNDROME, 1993, THE STURGE WEBER FOUNDATION 4 TH INTERNATIONAL MEETING 10) LUMIGAN, ALPHAGAN-P, A ROUND TABLE DISCUSSION, 2001, DENVER, 11) GLAUCOMA TREATMENT & GOALS, 2002, DENVER, 12) TARGET PRESSURES, 2002, FORT COLLINS, 13) GLAUCOMA & LIPID DRUGS, 2002, DENVER, 14) GLAUCOMA & IOP MANAGEMENT, 2002, ALBUQUERQUE, 15) LATANOPROST, BRIMATOPROST and TRAVOPROST

7 7 COMPARISON STUDY, 2003, ENGLEWOOD,PFIZER, INC. OPHTHALMICS 16) GLAUCOMA AND IOP GOALS, 2003, COLORADO SPRINGS, 17) GLAUCOMA AND IOP GOALS, 2003, COLORADO SPRINGS, 18) ROCKY MOUNTAIN GLAUCOMA JOURNAL CLUB, 2003, DENVER, (R.L. Shields, Moderator), 19) GLAUCOMA TRENDS, 2003, FORT COLLINS, PFIZER, INC. OPHTHALMICS 20) THE GLAUCOMA CASCADE: PROGRESSION, 2004, CANYON CITY, 21) GLAUCOMA: HOW IT PROGRESSES, 2004, BOULDER, ALCON PHARMACEUTICAL 22) GLAUCOMA PROGRESSION, 2004, TUCSON, 23) GLAUCOMA PROGRESSION, 2004, PHOENIX, 24) The GLAUCOMA EXAM, 2012, DENVER, RESIDENT LECTURE, UNIVERSITY OF COLORADO, DEPARTMENT OF OPHTHALMOLOGY PRECEPTOR FOR PAPERS: 1) Sharp D, Shields RL: Evaluation of the Cadar by Image Analysis in the Normal Optic Disc, ) Rottman R, Shields RL: Glaucoma Visual Field Progression, ) Philpott L, Shields RL: Correlation Between Automated Perimetry and Glaucomatous Optic Nerve Cupping, 1990 ARTICLES: 1) Elman J, Caprioli I, Rosanelli EG, Shields RL, Mead A, Sears M, Petillo J: Celiprolol Versus Timolol and Placebo, A Two Week Double Blind Comparison. Journal of Ocular Pharmacol. 3:5-10, ) Shields RL: Optic Nerve Analysis. Glaucoma. Volume 10, Number 3:83-84, May/June ) Craven ER, Shields RL: Tonometry in Clinical Practice. Clinical Signs in Ophthalmology Volume XII, Number 1, ) Silverman RH, et al: Therapeutic Ultrasound for the Treatment of Glaucoma. J. Ophthalmol. 111: , March 1991

8 8 5) Shields RL: Glaucoma Staging for the Octopus Perimeter by the Loss Statistic Submitted for publication ) Sherwood M, Brandt J: Six-Month Comparison of Bimatoprost Once- Daily and Twice-Daily with Timolol Twice-Daily in Patients with Survey of Ophthalmology. 45, Supplement 4:S361-S368, May ) Brandt J, VanDenburgh A, Kuankuan C, Whitcup S: Comparison of Once-or Twice-Daily Bimatoprost with Twice-daily Timolol in Patients with Elevated IOP. A 3-Month Clinical Trial. Ophthalmology. Volume 108, Number 6: , June ) Schuman, Joel S., et.al: Evaluation of Travoprost 0.004%/Timolol 0.5% Fixed Combination Ophthalmic Solution vs. Concomitant Use of Travoprost 0.004% and Timolol 0.5% Abstract AAO - New Orleans: October ) Whitson, Jess T., Brimonidine 0.15% Study Group, Shields, Robert L., Brimonidine 0.15% Study Group: "The Safety and Intraocular Pressure Lowering Efficacy of Brimonidine Tartrate 0.15% Preserved with Polyquaternium-1" American Academy of Ophthalmology 2006 ABSTRACTS 1) Holmboe M, Kahook MY, Shields RL, Seibold LK: Efficacy of the Ex-PRESS glaucoma drainage device in the treatment of glaucoma. ARVO 5016 B0215 [May 2015} PERSONAL INTERESTS: Downhill and Cross Country Skiing Photography Snorkeling Computers